Vendor Intelligence Report: Crestpeptide

Published 3 Jul 2026. 19-page investigative report on who is behind Crestpeptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Crestpeptide records 4 pass / 0 fail for a 100% overall pass rate. The signal is product-specific: Retatrutide is the tested strength and reads as a reasonable choice on Finnrick data, while the broader menu remains outside Finnrick coverage. With only one product and four samples, methodology sensitivity matters; the full report shows how the rating changes under stricter grading.

The operating-risk picture is less clean. Fieldwork found a live storefront on Crestpep.com, while the Crestpeptide.com intake domain was unreachable; neither domain had usable archived history to support the claimed multi-year timeline. The site uses a China location listing alongside Hong Kong legal framing and contact infrastructure, but does not disclose a registered operating company, named leadership, or physical address. A similarly named U.S. site was resolved as a separate competitor, not a sister brand.

Crestpeptide's COA library is a real buyer-positive step, but it is not independently anchored in the captured public materials. The library presents third-party and Janoshik testing claims while leaving the issuing laboratory unresolved, and the public Janoshik database did not return Crestpeptide entries. For non-Retatrutide items such as Semax, TB-500, and GHK-Cu, the practical read is simple: require a named-lab, lot-specific report or independent testing before extending confidence beyond Retatrutide.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data with Retatrutide pass/fail detail, rating trajectory, and methodology-divergence charts
  • Corporate identity and jurisdiction review covering Hong Kong registry searches, China-name variants, legal-forum language, and the Shanghai Crest Technology lead
  • COA-library verification analysis, including the unnamed-lab problem and the Janoshik public-database discrepancy
  • Domain-forensics and brand-confusion map for Crestpep.com, Crestpeptide.com, and the separate Crest-peptides.com competitor
  • Payment-rail and buyer-recourse analysis for crypto, bank transfer, Wise, and absent card chargeback protection
  • Reputation and promotion sweep across Reddit, X, LinkedIn, Trustpilot, Facebook, and coupon/referral searches

Risk assessment

  • Undisclosed operating-entity risk — high: No registered entity, physical address, or named leadership is disclosed; China listing, Hong Kong legal terms, and +852 contact remain unresolved.
  • Testing-lab verification risk — high: COA library promotes third-party testing, but lab identity is not publicly verifiable and Janoshik public database shows no Crestpeptide entries.
  • Non-Retatrutide catalog quality uncertainty — medium: Finnrick data covers only Retatrutide; Semax, TB/TB-500, Selank, PT-141, MOTS-C, GHK-Cu, and other catalog items lack Finnrick support.
  • Official-domain, history, and brand-confusion risk — medium: crestpep.com is active while crestpeptide.com was unreachable; neither domain had Wayback history and crest-peptides.com is a separate lookalike competitor.
  • Payment-protection risk — medium: Checkout relies on cryptocurrency, T/T, and Wise with no credit-card chargeback layer against an unnamed operator.